Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$5.60
+1.8%
$6.03
$1.35
$17.49
$19.99M0.71.95 million shs4,049 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$1.39
+1.1%
$1.45
$0.65
$2.12
$103.49M2.29338,213 shs61,023 shs
Imunon, Inc. stock logo
CLSN
Imunon
$2.22
$1.80
$15.75
$13.91M2.27150,471 shs711 shs
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$0.64
C$0.64
C$0.38
C$8.17
C$90.27MN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$0.04
$0.04
$0.03
$0.06
$6.20M0.62275,662 shs80,457 shs
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
-2.83%-28.10%-29.03%+225.44%+87.07%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-2.84%+19.13%-19.88%+11.38%+24.55%
Imunon, Inc. stock logo
CLSN
Imunon
0.00%0.00%0.00%0.00%0.00%
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.00%0.00%0.00%0.00%0.00%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
0.00%-2.06%+5.56%+6.44%-15.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.8535 of 5 stars
3.55.00.00.01.91.70.6
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3.00
Buy$4.75242.96% Upside
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest CLSD, CVSI, APM, CLSN, and CTST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/14/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
3/13/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00
3/13/2024
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00 ➝ $4.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$1.30M15.38N/AN/A$2.19 per share2.56
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$8.23M12.57N/AN/A($0.25) per share-5.54
Imunon, Inc. stock logo
CLSN
Imunon
$500K0.00N/AN/A$9.66 per share0.00
CannTrust Holdings Inc stock logo
CTST
CannTrust
C$35.22M2.56N/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$16M0.39$0.02 per share1.80$0.02 per share1.90

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$9.80MN/A0.00N/AN/AN/AN/A4/26/2024 (Estimated)
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$32.49M-$0.53N/AN/AN/A-394.91%N/A-85.31%5/9/2024 (Estimated)
Imunon, Inc. stock logo
CLSN
Imunon
-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
-C$10.46MN/A0.00N/AN/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
$3.10M$0.021.90N/A19.38%80.98%30.87%N/A

Latest CLSD, CVSI, APM, CLSN, and CTST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A-$0.01-$0.01-$0.01N/A$3.80 million
3/12/2024Q4 2023
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$0.10-$0.08+$0.02-$0.08$3.40 million$6.35 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/A
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
4.42
4.42
Imunon, Inc. stock logo
CLSN
Imunon
0.13
6.52
6.52
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/AN/AN/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A
1.30
0.37

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Imunon, Inc. stock logo
CLSN
Imunon
12.97%
CannTrust Holdings Inc stock logo
CTST
CannTrust
0.03%
CV Sciences, Inc. stock logo
CVSI
CV Sciences
N/A

Insider Ownership

CompanyInsider Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
9.80%
Imunon, Inc. stock logo
CLSN
Imunon
4.66%
CannTrust Holdings Inc stock logo
CTST
CannTrust
N/A
CV Sciences, Inc. stock logo
CVSI
CV Sciences
1.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
183.57 million1.29 millionNot Optionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
3074.72 million67.40 millionOptionable
Imunon, Inc. stock logo
CLSN
Imunon
277.10 million6.77 millionOptionable
CannTrust Holdings Inc stock logo
CTST
CannTrust
576141.49 millionN/AOptionable
CV Sciences, Inc. stock logo
CVSI
CV Sciences
42163.23 million161.11 millionNot Optionable

CLSD, CVSI, APM, CLSN, and CTST Headlines

SourceHeadline
CV Sciences, Inc. (PNK:CVSI) Q4 2023 Earnings Call TranscriptCV Sciences, Inc. (PNK:CVSI) Q4 2023 Earnings Call Transcript
finance.yahoo.com - April 1 at 7:04 PM
CVSI Stock Earnings: CV Sciences Reported Results for Q4 2023CVSI Stock Earnings: CV Sciences Reported Results for Q4 2023
investorplace.com - March 28 at 3:10 PM
CV Sciences, Inc. Reports Fiscal Year-End 2023 Financial ResultsCV Sciences, Inc. Reports Fiscal Year-End 2023 Financial Results
prnewswire.com - March 28 at 9:00 AM
CV Sciences Inc.CV Sciences Inc.
wsj.com - March 27 at 9:29 AM
CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews
finance.yahoo.com - March 26 at 8:39 AM
CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024CV SCIENCES, INC. TO ANNOUNCE YEAR END AND FOURTH QUARTER 2023 RESULTS ON MARCH 28, 2024
prnewswire.com - March 21 at 9:00 AM
CV Sciences Stock (OTC:CVSI), Short Interest ReportCV Sciences Stock (OTC:CVSI), Short Interest Report
benzinga.com - February 22 at 4:06 AM
CV Sciences Expands into European Plant-Based Food Market with Acquisition of Cultured FoodsCV Sciences Expands into European Plant-Based Food Market with Acquisition of Cultured Foods
vegconomist.com - December 12 at 4:06 PM
CV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European DistributionCV Sciences, Inc. Acquires Cultured Foods To Enter Plant-Based Food Market, Opening Door For European Distribution
finance.yahoo.com - December 12 at 9:52 AM
The Best Shampoo for Thinning Hair We Tested Is 30% Off Right NowThe Best Shampoo for Thinning Hair We Tested Is 30% Off Right Now
nz.finance.yahoo.com - November 15 at 3:19 PM
CV Sciences, Inc. (PNK:CVSI) Q3 2023 Earnings Call TranscriptCV Sciences, Inc. (PNK:CVSI) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 15 at 3:19 PM
Hemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%Hemp-Focused Wellness Company: Revenue Jumps To $4.1M, Gross Margin Peaks At 45.1%
benzinga.com - November 14 at 3:22 PM
CV Sciences GAAP EPS of $0.00, revenue of $4.09MCV Sciences GAAP EPS of $0.00, revenue of $4.09M
msn.com - November 14 at 1:07 PM
CV Sciences, Inc. Reports Third Quarter 2023 Financial ResultsCV Sciences, Inc. Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 14 at 1:07 PM
CV Sciences Inc CVSICV Sciences Inc CVSI
morningstar.com - November 12 at 8:46 PM
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2023 RESULTS ON NOVEMBER 14, 2023
finance.yahoo.com - November 9 at 1:25 PM
Sham Procedures in CV Research: What’s Sacrificed for Science?Sham Procedures in CV Research: What’s Sacrificed for Science?
tctmd.com - October 24 at 9:08 AM
Graduate puts spotlight on CV Tech’s biomed programGraduate puts spotlight on CV Tech’s biomed program
journalrecord.com - October 10 at 5:43 PM
CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. Launches Reserve Sleep Gummies
finance.yahoo.com - September 5 at 8:24 AM
CV Sciences, Inc. (PNK:CVSI) Q2 2023 Earnings Call TranscriptCV Sciences, Inc. (PNK:CVSI) Q2 2023 Earnings Call Transcript
finance.yahoo.com - August 15 at 6:30 PM
CV Sciences GAAP EPS of -$0.01, revenue of $4MCV Sciences GAAP EPS of -$0.01, revenue of $4M
seekingalpha.com - August 14 at 4:38 PM
Publicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To KnowPublicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To Know
benzinga.com - August 14 at 4:38 PM
CV Sciences, Inc. Reports Second Quarter 2023 Financial ResultsCV Sciences, Inc. Reports Second Quarter 2023 Financial Results
finance.yahoo.com - August 14 at 4:38 PM
CV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023CV SCIENCES, INC. TO ANNOUNCE SECOND QUARTER 2023 RESULTS ON AUGUST 14, 2023
finance.yahoo.com - August 1 at 4:45 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptorum Group logo

Aptorum Group

NASDAQ:APM
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
Clearside Biomedical logo

Clearside Biomedical

NASDAQ:CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Imunon logo

Imunon

NASDAQ:CLSN
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
CannTrust logo

CannTrust

NYSE:CTST
CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.
CV Sciences logo

CV Sciences

OTCMKTS:CVSI
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.